Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three‐yr results of a single‐center prospective clinical trial

• DOI: 10.1111/ctr.12141
• Publication Date: 2013-05-27T01:52:48Z
• Authors: Evaldo Favi; Gionata Spagnoletti; Maria P. Salerno; José A. Pedroso; Jacopo Romagnoli; Franco Citterio
• Keywords: Everolimus; Basiliximab; Regimen; Discontinuation; Sirolimus; Single Center; Mycophenolate; Immunosuppression

Abstract We compared in kidney transplantation two immunosuppressive regimens: tacrolimus plus mycophenolate mofetil (MMF) ( TAC ) and everolimus low‐dose cyclosporine EVE ). Sixty consecutive patients received (30 patients) or as regimen; all subjects also induction with basiliximab corticosteroids. After three‐yr follow‐up, no difference was found patient graft survival PTS : TAC: 97% vs. 100%; GS: 93% 93%). The incidence of acute rejection higher the group but not statistically significant (17% 23%, p = ns). Patients showed serum cholesterol (205 ± 41 235 mg/ dL , 0.0012) lower hemoglobin concentration (13.6 1.4 12.4 1.9, 0.01). Renal function significantly different groups (3 Y creatinine: 0.8 1.6 Treatment discontinuation 17 36%, Our data show that middle‐term an regimen MMF has a similar efficacy safety profile comparison combination low‐exposure everolimus. Further follow up could evidence benefits related to anti‐proliferative effects